cisplatin,carboplatin,atezolizumab
roche
['atezo', 'cisplatin', 'imvigor 130', 'imvigor130', 'core 1', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'carboplatin', 'imvigor,11', 'lba441', 'bladder']
atezolizumab monotherapy did not provide an os benefit over chemotherapy (hr, 0.98;
95% ci: 0.82, 1.16).exploratory efficacy data suggest a clinical benefit with atezolizumab monotherapy as 1l treatment for cisplatin-ineligible patients with pd-l1 ic2/3 muc. #gu23 #bladdercancer 
Jefe de Servicio de Oncología Médica. Hospital Universitario Lucus Augusti, HULA. Grupo de Investigación Oncológica Traslacional, GIOT HULA. Cuenta personal